- Conditions
- Sporadic Inclusion Body Myositis
- Interventions
- BYM338, Placebo
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Kansas City, Kansas • Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–37
of 13
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Sporadic Inclusion Body Myositis (sIBM)
- Interventions
- BYM338 (Bimagrumab)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Boston, Massachusetts
- Conditions
- Inclusion Body Myositis
- Interventions
- Etanercept
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Dermatomyositis, Inclusion Body Myositis, Polymyositis
- Interventions
- Gamma Globulin
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1990 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
- Interventions
- Pozelimab/Cemdisiran
- Combination Product
- Lead sponsor
- Austin Neuromuscular Center
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Polymyositis, Dermatomyositis
- Interventions
- BAF312, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Inclusion Body Myositis
- Interventions
- Arimoclomol, Placebo
- Drug · Other
- Lead sponsor
- ZevraDenmark
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Irvine, California • Aurora, Colorado + 8 more
- Conditions
- Healthy
- Interventions
- CaHMB, HMB Free Acid Gel, Placebo, Placebo Gel Dosage
- Dietary Supplement
- Lead sponsor
- Metabolic Technologies Inc.
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Ames, Iowa
- Conditions
- Muscle Damage, Muscle Inflammation
- Interventions
- Lovaza (omega-3-acid ethyl esters), Wheat Germ Oil
- Drug
- Lead sponsor
- Western Michigan University
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Kalamazoo, Michigan
- Conditions
- Sporadic Inclusion Body Myositis
- Interventions
- BYM338/bimagrumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 36 Years to 85 Years
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Orange, California • Sacramento, California + 8 more
- Conditions
- Inclusion Body Myositis
- Interventions
- Adipose Derived Regenerative Cells
- Device
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Pain, Weakness, Cramps, Myalgia or Myositis Nos, HMG COA Reductase Inhibitor Adverse Reaction
- Interventions
- Coenzyme Q10, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Catherine Buettner
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Dermatomyositis, Polymyositis, Inclusion Body Myositis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 2 Years to 100 Years
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 1995
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Bethesda, Maryland • Research Triangle Park, North Carolina + 1 more